Navigation Links
Combination therapy reduced HER2-positive breast cancers
Date:12/10/2010

SAN ANTONIO A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

  • U.S. and Canada: (888) 282-7404
  • International: (706) 679-5207
  • Access Code: 25346432

Lead researcher Jos Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone.

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease," said Baselga, who is also a founding editor-in-chief of the AACR's newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

"It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting," said Baselga.

At the symposium, Baselga presented the primary outcome of tumor rate after surgery, as well as the secondary outcomes of objective response rate, safety, pathologic node-negative status, rate of conversion to breast conservation, disease free survival and overall survival.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
2. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
3. Grape news: New treatment combination safe alternative to sulfur dioxide
4. Study: Grass, fungus combination affects ecology
5. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
6. Diabetes drug kills cancer stem cells in combination treatment in mice
7. Old stain in a new combination
8. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
9. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
10. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop and ... downtown Boston at 745 Atlantic Ave. , “We are seeing that even the ... value they provide, not just to patients, but also payers. Having a presence in ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ ... American Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today ... AAB’s commitment to excellence in clinical laboratory services and regulations. , “We ...
(Date:5/19/2017)... Philadelphia, PA (PRWEB) , ... May 19, 2017 ... ... for its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, ... Pennsylvania, New Jersey and Delaware, are encouraged to submit proposals. QED, now in ...
Breaking Biology Technology: